NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
Clinical Trials
60 trialsNCT00770809 2025-08-15
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01273610 2025-06-10
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00490139 2025-03-21
ALTTO
Novartis
Phase 3 Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00470704 2024-12-19
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01622868 2023-10-17
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT00952692 2021-12-20
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
Duke University
Phase 1/2 Completed
NCT00444535 2021-10-25
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT00206427 2021-09-29
GW
Baylor Breast Care Center
Phase 2 Completed
NCT00508274 2021-09-21
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Novartis
Phase 3 Terminated
NCT00553358 2021-09-21
Neo ALTTO
Novartis
Phase 3 Completed
NCT00073528 2021-02-24
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00684983 2020-03-24
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00331630 2020-03-06
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00390455 2019-12-20
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
National Cancer Institute (NCI)
Phase 3 Completed
NCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT00820872 2019-10-21
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00759642 2019-07-01
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
University of Kansas Medical Center
Phase 2 Terminated
NCT00820222 2019-04-02
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00320411 2019-01-31
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00477464 2018-09-17
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00225758 2018-07-27
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT00118157 2017-12-04
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
National Cancer Institute (NCI)
Phase 2 Completed
NCT01688609 2017-09-11
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00721630 2017-08-15
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01868503 2017-06-26
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Stanford University
Phase 2 Terminated
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT00482391 2017-05-12
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00496366 2017-03-21
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00089999 2017-02-28
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00524303 2016-11-11
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
GlaxoSmithKline
Phase 2 Completed
NCT00829166 2016-10-31
EMILIA
Hoffmann-La Roche
Phase 3 Completed
NCT00422903 2016-05-12
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT00320385 2016-02-26
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00632489 2015-06-08
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00075270 2015-05-06
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed